Navigation Links
American Oriental Bioengineering Announces Participation in September Investor Conferences

NEW YORK, Sept. 4 /PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), a leading manufacturer and distributor of plant-based pharmaceutical and nutraceutical products in China, today announced that the Company will attend the Credit Suisse Asian Technology Conference -- China Day on September 10, 2007 in Shenzhen, China as well as the 3rd Semi-Annual Investor Tour of Mainland China hosted by Brean Murray Carret & Co. on September 11, 2007 in Beijing, China.

AOBO management will meet individually with institutional investors attending the Credit Suisse Asian Technology Conference at the Crowne Plaza Hotel in Shenzhen, China on September 10, 2007. In addition, Tony Liu, CEO of AOBO will join a lunch panel discussion at 1:00 pm Beijing Standard Time along with presenters from other Chinese healthcare companies to discuss the recent developments in the China's healthcare industry. Investors interested in attending this event should contact their Credit Suisse institutional sales representative.

AOBO management is scheduled to present at the Brean Murray China Tour on September 11, 2007 at 12:00 pm Beijing Standard Time at the Grand Hyatt Hotel in Beijing. Attendees are also invited to tour the Company's pharmaceutical manufacturing facility and nutraceutical manufacturing facility in Harbin, China on Saturday, September 8, 2007. Investors interested in attending this event should contact their Brean Murray institutional sales representative.


American Oriental Bioengineering Inc. (AOBO) is engaged in the development and production of plant-based pharmaceutical products and plant-based nutraceutical products widely distributed throughout China. For more information, visit

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

SOURCE American Oriental Bioengineering, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. A disgusting video: U.S. companies sell out Americans
2. Northwestern Mutual, American Family make Computerworlds best IT workplaces
3. Brazilian bio-industry should impress American investors
4. CIO Leadership Series: Byrne Chapman, American Family Insurance
5. Metavante fires 180 North American workers
6. 300 millionth American no cause for eco-alarm
7. American Idol spurs music software
8. Healthcare software addresses "90 million" misclassified Americans
9. Technology and the "American" dream
10. Peters: Innovation the only edge that remains for American business
11. We are American No sex, please
Post Your Comments:
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology:
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
Breaking Biology News(10 mins):